{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T12:40:31Z","timestamp":1766407231503,"version":"3.41.2"},"reference-count":59,"publisher":"Becaris Publishing Limited","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Comp. Eff. Res."],"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:p>\n            <jats:bold>Aim:<\/jats:bold>\n            To evaluate the clinical and economic impact of antiarrhythmic drugs (AADs) compared with ablation both as individual treatments and as combination therapy without\/with considering the order of treatment among patients with atrial fibrillation (AFib).\n            <jats:bold>Materials &amp; methods:<\/jats:bold>\n            A budget impact model over a one-year time horizon was developed to assess the economic impact of AADs (amiodarone, dofetilide, dronedarone, flecainide, propafenone, sotalol, and as a group) versus ablation across three scenarios: direct comparisons of individual treatments, non-temporal combinations, and temporal combinations. The economic analysis was conducted in accordance with CHEERS guidance as per current model objectives. Results are reported as costs per patient per year (PPPY). The impact of individual parameters was evaluated using one-way sensitivity analysis (OWSA).\n            <jats:bold>Results:<\/jats:bold>\n            In direct comparisons, ablation had the highest annual medication\/procedure cost ($29,432), followed by dofetilide ($7661), dronedarone ($6451), sotalol ($4552), propafenone ($3044), flecainide ($2563), and amiodarone ($2538). Flecainide had the highest costs for long-term clinical outcomes ($22,964), followed by dofetilide ($17,462), sotalol ($15,030), amiodarone ($12,450), dronedarone ($10,424), propafenone ($7678) and ablation ($9948). In the non-temporal scenario, total costs incurred for AADs (group)\u00a0+\u00a0ablation ($17,278) were lower compared with ablation alone ($39,380). In the temporal scenario, AADs (group) before ablation resulted in PPPY cost savings of ($22,858) compared with AADs (group) after ablation ($19,958). Key factors in OWSA were ablation costs, the proportion of patients having reablation, and withdrawal due to adverse events.\n            <jats:bold>Conclusion:<\/jats:bold>\n            Utilization of AADs as individual treatment or in combination with ablation demonstrated comparable clinical benefits along with costs savings in patients with AFib.\n          <\/jats:p>","DOI":"10.57264\/cer-2023-0065","type":"journal-article","created":{"date-parts":[[2023,6,30]],"date-time":"2023-06-30T11:02:01Z","timestamp":1688122921000},"source":"Crossref","is-referenced-by-count":1,"title":["Clinical and economic outcomes associated with use of anti-arrhythmic drugs versus ablation in atrial fibrillation"],"prefix":"10.57264","volume":"12","author":[{"given":"Jennifer","family":"Ken-Opurum","sequence":"first","affiliation":[{"name":"Axtria Inc., Berkley Heights, NJ\u00a007922, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sesha SS","family":"Srinivas","sequence":"additional","affiliation":[{"name":"Axtria Inc., Berkley Heights, NJ\u00a007922, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seojin","family":"Park","sequence":"additional","affiliation":[{"name":"Sanofi US, Bridgewater, NJ\u00a008807, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott","family":"Charland","sequence":"additional","affiliation":[{"name":"Sanofi US, Bridgewater, NJ\u00a008807, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Revel","sequence":"additional","affiliation":[{"name":"Sanofi US, Bridgewater, NJ\u00a008807, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald","family":"Preblick","sequence":"additional","affiliation":[{"name":"Sanofi US, Bridgewater, NJ\u00a008807, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"36897","reference":[{"issue":"8","key":"e_1_3_6_3_2","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1161\/CIRCULATIONAHA.113.005119","article-title":"Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study","volume":"129","author":"Chugh SS","year":"2014","unstructured":"Chugh SS, Havmoeller R, Narayanan K Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation 129(8), 837\u2013847 (2014).","journal-title":"Circulation"},{"issue":"10","key":"e_1_3_6_4_2","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1161\/01.CIR.98.10.946","article-title":"Impact of atrial fibrillation on the risk of death: the Framingham Heart Study","volume":"98","author":"Benjamin EJ","year":"1998","unstructured":"Benjamin EJ, Wolf PA, D'Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation 98(10), 946\u2013952 (1998).","journal-title":"Circulation"},{"issue":"9","key":"e_1_3_6_5_2","doi-asserted-by":"crossref","first-page":"650","DOI":"10.7326\/M14-0538","article-title":"Association between atrial fibrillation and silent cerebral infarctions: a systematic review and meta-analysis","volume":"161","author":"Kalantarian S","year":"2014","unstructured":"Kalantarian S, Ay H, Gollub RL Association between atrial fibrillation and silent cerebral infarctions: a systematic review and meta-analysis. Ann. Intern. Med. 161(9), 650\u2013658 (2014).","journal-title":"Ann. Intern. Med."},{"key":"e_1_3_6_6_2","unstructured":"Centers for Disease Control and Prevention. Atrial Fibrillation. www.cdc.gov\/heartdisease\/atrial_fibrillation.htm. (2023)."},{"issue":"10","key":"e_1_3_6_7_2","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1161\/CIR.0000000000000659","article-title":"Heart disease and stroke statistics-2019 update: a report from the American Heart Association","volume":"139","author":"Benjamin EJ","year":"2019","unstructured":"Benjamin EJ, Muntner P, Alonso A Heart disease and stroke statistics-2019 update: a report from the American Heart Association. Circulation 139(10), e56\u2013e528 (2019).","journal-title":"Circulation"},{"issue":"8","key":"e_1_3_6_8_2","first-page":"e153","article-title":"Heart disease and stroke statistics-2022 update: a report from the American Heart Association","volume":"145","author":"Tsao CW","year":"2022","unstructured":"Tsao CW, Aday AW, Almarzooq ZI Heart disease and stroke statistics-2022 update: a report from the American Heart Association. Circulation 145(8), e153\u2013e639 (2022).","journal-title":"Circulation"},{"key":"e_1_3_6_9_2","unstructured":"Mayo Clinic. Atrial fibrillation. www.mayoclinic.org\/diseases-conditions\/atrial-fibrillation\/symptoms-causes\/syc-20350624. (2023)."},{"issue":"23","key":"e_1_3_6_10_2","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.1161\/CIRCULATIONAHA.111.069450","article-title":"Symptoms and functional status of patients with atrial fibrillation: state of the art and future research opportunities","volume":"125","author":"Rienstra M","year":"2012","unstructured":"Rienstra M, Lubitz SA, Mahida S Symptoms and functional status of patients with atrial fibrillation: state of the art and future research opportunities. Circulation 125(23), 2933\u20132943 (2012).","journal-title":"Circulation"},{"issue":"5","key":"e_1_3_6_11_2","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/j.1524-4733.2006.00124.x","article-title":"Assessing the direct costs of treating nonvalvular atrial fibrillation in the United States","volume":"9","author":"Coyne KS","year":"2006","unstructured":"Coyne KS, Paramore C, Grandy S, Mercader M, Reynolds M, Zimetbaum P. Assessing the direct costs of treating nonvalvular atrial fibrillation in the United States. Value Health 9(5), 348\u2013356 (2006).","journal-title":"Value Health"},{"key":"e_1_3_6_12_2","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.amjcard.2020.10.023","article-title":"Economic impact of atrial fibrillation on hospitalization outcomes of acute heart failure in the United States","volume":"138","author":"Abugroun A","year":"2021","unstructured":"Abugroun A, Taha A, Abdel-Rahman M, Volgman AS. Economic impact of atrial fibrillation on hospitalization outcomes of acute heart failure in the United States. Am. J. Cardiol. 138, 124\u2013127 (2021).","journal-title":"Am. J. Cardiol."},{"issue":"3","key":"e_1_3_6_13_2","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1161\/CIRCOUTCOMES.110.958165","article-title":"Estimation of total incremental health care costs in patients with atrial fibrillation in the United States","volume":"4","author":"Kim MH","year":"2011","unstructured":"Kim MH, Johnston SS, Chu BC, Dalal MR, Schulman KL. Estimation of total incremental health care costs in patients with atrial fibrillation in the United States. Circ. Cardiovasc. Qual. Outcomes 4(3), 313\u2013320 (2011).","journal-title":"Circ. Cardiovasc. Qual. Outcomes"},{"issue":"10","key":"e_1_3_6_14_2","doi-asserted-by":"crossref","first-page":"e014932","DOI":"10.1161\/JAHA.119.014932","article-title":"Comprehensive management with the ABC (Atrial Fibrillation Better Care) Pathway in clinically complex patients with atrial fibrillation: a post hoc ancillary analysis from the AFFIRM Trial","volume":"9","author":"Proietti M","year":"2020","unstructured":"Proietti M, Romiti GF, Olshansky B, Lane DA, Lip GYH. Comprehensive management with the ABC (Atrial Fibrillation Better Care) Pathway in clinically complex patients with atrial fibrillation: a post hoc ancillary analysis from the AFFIRM Trial. J. Am. Heart Assoc. 9(10), e014932 (2020).","journal-title":"J. Am. Heart Assoc."},{"issue":"11","key":"e_1_3_6_15_2","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/nrcardio.2017.153","article-title":"The ABC pathway: an integrated approach to improve AF management","volume":"14","author":"Lip GYH","year":"2017","unstructured":"Lip GYH. The ABC pathway: an integrated approach to improve AF management. Nat. Rev. Cardiol. 14(11), 627\u2013628 (2017).","journal-title":"Nat. Rev. Cardiol."},{"issue":"7","key":"e_1_3_6_16_2","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1056\/NEJMoa0803778","article-title":"Effect of dronedarone on cardiovascular events in atrial fibrillation","volume":"360","author":"Hohnloser SH","year":"2009","unstructured":"Hohnloser SH, Crijns HJ, van Eickels M Effect of dronedarone on cardiovascular events in atrial fibrillation. N. Engl. J. Med. 360(7), 668\u2013678 (2009).","journal-title":"N. Engl. J. Med."},{"issue":"14","key":"e_1_3_6_17_2","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1056\/NEJMoa2019422","article-title":"Early rhythm-control therapy in patients with atrial fibrillation","volume":"383","author":"Kirchhof P","year":"2020","unstructured":"Kirchhof P, Camm AJ, Goette A Early rhythm-control therapy in patients with atrial fibrillation. N. Engl. J. Med. 383(14), 1305\u20131316 (2020).","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"e_1_3_6_18_2","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1056\/NEJMoa2029980","article-title":"Cryoablation or drug therapy for initial treatment of atrial fibrillation","volume":"384","author":"Andrade JG","year":"2021","unstructured":"Andrade JG, Wells GA, Deyell MW Cryoablation or drug therapy for initial treatment of atrial fibrillation. N. Engl. J. Med. 384(4), 305\u2013315 (2021).","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"e_1_3_6_19_2","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1093\/europace\/euaa298","article-title":"Catheter ablation or medical therapy to delay progression of atrial fibrillation: the randomized controlled atrial fibrillation progression trial (ATTEST)","volume":"23","author":"Kuck KH","year":"2021","unstructured":"Kuck KH, Lebedev DS, Mikhaylov EN Catheter ablation or medical therapy to delay progression of atrial fibrillation: the randomized controlled atrial fibrillation progression trial (ATTEST). Europace 23(3), 362\u2013369 (2021).","journal-title":"Europace"},{"issue":"9","key":"e_1_3_6_20_2","article-title":"Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation","volume":"9","author":"Valembois L","year":"2019","unstructured":"Valembois L, Audureau E, Takeda A, Jarzebowski W, Belmin J, Lafuente-Lafuente C. Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation. Cochrane Database Syst. Rev. 9(9), DOI: 10.1002\/14651858.CD005049.pub5 (2019).","journal-title":"Cochrane Database Syst. Rev."},{"issue":"21","key":"e_1_3_6_21_2","first-page":"e1","article-title":"2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society","volume":"64","author":"January CT","year":"2014","unstructured":"January CT, Wann LS, Alpert JS 2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J. Am. Coll. Cardiol. 64(21), e1\u2013e76 (2014).","journal-title":"J. Am. Coll. Cardiol."},{"issue":"5","key":"e_1_3_6_22_2","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJMoa1707855","article-title":"Catheter ablation for atrial fibrillation with heart failure","volume":"378","author":"Marrouche NF","year":"2018","unstructured":"Marrouche NF, Brachmann J, Andresen D Catheter ablation for atrial fibrillation with heart failure. N. Engl. J. Med. 378(5), 417\u2013427 (2018).","journal-title":"N. Engl. J. Med."},{"issue":"14","key":"e_1_3_6_23_2","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1161\/CIRCULATIONAHA.120.050991","article-title":"Ablation versus drug therapy for atrial fibrillation in heart failure: results from the CABANA Trial","volume":"143","author":"Packer DL","year":"2021","unstructured":"Packer DL, Piccini JP, Monahan KH Ablation versus drug therapy for atrial fibrillation in heart failure: results from the CABANA Trial. Circulation 143(14), 1377\u20131390 (2021).","journal-title":"Circulation"},{"issue":"4","key":"e_1_3_6_24_2","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2029554","article-title":"Cryoballoon ablation as initial therapy for atrial fibrillation","volume":"384","author":"Wazni OM","year":"2021","unstructured":"Wazni OM, Dandamudi G, Sood N Cryoballoon ablation as initial therapy for atrial fibrillation. N. Engl. J. Med. 384(4), 316\u2013324 (2021).","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"e_1_3_6_25_2","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","article-title":"2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC","volume":"42","author":"Hindricks G","year":"2021","unstructured":"Hindricks G, Potpara T, Dagres N 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur. Heart J. 42(5), 373\u2013498 (2021).","journal-title":"Eur. Heart J."},{"issue":"4","key":"e_1_3_6_26_2","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1111\/jce.14979","article-title":"Safety and complications of catheter ablation for atrial fibrillation: predictors of complications from an updated analysis the National Inpatient Database","volume":"32","author":"Wu L","year":"2021","unstructured":"Wu L, Narasimhan B, Ho KS, Zheng Y, Shah AN, Kantharia BK. Safety and complications of catheter ablation for atrial fibrillation: predictors of complications from an updated analysis the National Inpatient Database. J. Cardiovasc. Electrophysiol. 32(4), 1024\u20131034 (2021).","journal-title":"J. Cardiovasc. Electrophysiol."},{"issue":"11","key":"e_1_3_6_27_2","article-title":"Efficacy and safety of ablation for people with non-paroxysmal atrial fibrillation","volume":"11","author":"Nyong J","year":"2016","unstructured":"Nyong J, Amit G, Adler AJ Efficacy and safety of ablation for people with non-paroxysmal atrial fibrillation. Cochrane Database Syst. Rev. 11(11), DOI: 10.1002\/14651858.CD012088.pub2 (2016).","journal-title":"Cochrane Database Syst. Rev."},{"key":"e_1_3_6_28_2","doi-asserted-by":"crossref","unstructured":"Husereau D Drummond M Augustovski F Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations.. CHEERS 2022 ISPOR Good Research Practices Task Force.","DOI":"10.1136\/bmj-2021-067975"},{"issue":"17","key":"e_1_3_6_29_2","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1161\/CIRCULATIONAHA.118.035455","article-title":"Modernized classification of cardiac antiarrhythmic drugs","volume":"138","author":"Lei M","year":"2018","unstructured":"Lei M, Wu L, Terrar DA, Huang CL. Modernized classification of cardiac antiarrhythmic drugs. Circulation 138(17), 1879\u20131896 (2018).","journal-title":"Circulation"},{"issue":"3","key":"e_1_3_6_30_2","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1093\/europace\/euq450","article-title":"Mixed treatment comparison of dronedarone, amiodarone, sotalol, flecainide, and propafenone, for the management of atrial fibrillation","volume":"13","author":"Freemantle N","year":"2011","unstructured":"Freemantle N, Lafuente-Lafuente C, Mitchell S, Eckert L, Reynolds M. Mixed treatment comparison of dronedarone, amiodarone, sotalol, flecainide, and propafenone, for the management of atrial fibrillation. Europace 13(3), 329\u2013345 (2011).","journal-title":"Europace"},{"key":"e_1_3_6_31_2","unstructured":"Consumer Price Index Inflation Calculator. (bls.gov) (2021). www.bls.gov\/data\/inflation_calculator.htm"},{"issue":"4","key":"e_1_3_6_32_2","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1161\/CIRCEP.108.837294","article-title":"Cost-effectiveness of radiofrequency catheter ablation compared with antiarrhythmic drug therapy for paroxysmal atrial fibrillation","volume":"2","author":"Reynolds MR","year":"2009","unstructured":"Reynolds MR, Zimetbaum P, Josephson ME, Ellis E, Danilov T, Cohen DJ. Cost-effectiveness of radiofrequency catheter ablation compared with antiarrhythmic drug therapy for paroxysmal atrial fibrillation. Circ. Arrhythm Electrophysiol. 2(4), 362\u2013369 (2009).","journal-title":"Circ. Arrhythm Electrophysiol."},{"issue":"3","key":"e_1_3_6_33_2","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s40273-013-0028-7","article-title":"Cost effectiveness of antiarrhythmic medications in patients suffering from atrial fibrillation","volume":"31","author":"Bruggenjurgen B","year":"2013","unstructured":"Bruggenjurgen B, Kohler S, Ezzat N, Reinhold T, Willich SN. Cost effectiveness of antiarrhythmic medications in patients suffering from atrial fibrillation. Pharmacoeconomics 31(3), 195\u2013213 (2013).","journal-title":"Pharmacoeconomics"},{"issue":"17","key":"e_1_3_6_34_2","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1016\/0002-9149(91)90326-G","article-title":"Comparative cost-effectiveness analysis of quinidine, procainamide and mexiletine","volume":"68","author":"Podrid PJ","year":"1991","unstructured":"Podrid PJ, Kowey PR, Frishman WH Comparative cost-effectiveness analysis of quinidine, procainamide and mexiletine. Am. J. Cardiol. 68(17), 1662\u20131667 (1991).","journal-title":"Am. J. Cardiol."},{"issue":"7","key":"e_1_3_6_35_2","doi-asserted-by":"crossref","first-page":"481","DOI":"10.3111\/13696998.2014.911185","article-title":"Cost-effectiveness of the convergent procedure and catheter ablation for non-paroxysmal atrial fibrillation","volume":"17","author":"Anderson LH","year":"2014","unstructured":"Anderson LH, Black EJ, Civello KC, Martinson MS, Kress DC. Cost-effectiveness of the convergent procedure and catheter ablation for non-paroxysmal atrial fibrillation. J. Med. Econ. 17(7), 481\u2013491 (2014).","journal-title":"J. Med. Econ."},{"issue":"1","key":"e_1_3_6_36_2","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-16938-6","article-title":"Predictors of atrial fibrillation recurrence after catheter ablation: data from the German Ablation Registry","volume":"7","author":"Sultan A","year":"2017","unstructured":"Sultan A, Luker J, Andresen D Predictors of atrial fibrillation recurrence after catheter ablation: data from the German Ablation Registry. Sci. Rep. 7(1), DOI: 10.1038\/s41598-017-16938-6 (2017).","journal-title":"Sci. Rep."},{"issue":"5","key":"e_1_3_6_37_2","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1093\/europace\/euy326","article-title":"Repeat procedure is a new independent predictor of complications of atrial fibrillation ablation","volume":"21","author":"Szegedi N","year":"2019","unstructured":"Szegedi N, Sz\u00e9plaki G, Herczeg S Repeat procedure is a new independent predictor of complications of atrial fibrillation ablation. Europace. 21(5), 732\u2013737 (2019).","journal-title":"Europace."},{"key":"e_1_3_6_38_2","unstructured":"Findacode.com. www.findacode.com\/index.html. (2022)."},{"issue":"1","key":"e_1_3_6_39_2","first-page":"5","article-title":"Prices Paid to Hospitals by Private Health Plans: Findings from Round 4 of an Employer-Led Transparency Initiative","volume":"10","author":"Whaley CM","year":"2022","unstructured":"Whaley CM, Briscombe B, Kerber R, O'Neill B, Kofner A. Prices Paid to Hospitals by Private Health Plans: Findings from Round 4 of an Employer-Led Transparency Initiative. Rand Health Q. 10(1), 5 (2022).","journal-title":"Rand Health Q"},{"issue":"2","key":"e_1_3_6_40_2","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s10840-021-01011-0","article-title":"Treatment success and its predictors as well as the complications of catheter ablation for atrial fibrillation in a high-volume centre","volume":"63","author":"Numminen A","year":"2022","unstructured":"Numminen A, Penttila T, Arola O Treatment success and its predictors as well as the complications of catheter ablation for atrial fibrillation in a high-volume centre. J. Interv. Card. Electrophysiol. 63(2), 357\u2013367 (2022).","journal-title":"J. Interv. Card. Electrophysiol."},{"key":"e_1_3_6_41_2","unstructured":"Center for Medicare & Medicaid Services. Physician Fee Schedule Look-Up Tool (HCPCS code 99214). www.cms.gov\/medicare\/physician-fee-schedule\/search?Y=0&T=4&HT=0&CT=3&H1=99214&M=5. (2021)."},{"issue":"5","key":"e_1_3_6_42_2","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1345\/aph.1L698","article-title":"Cost of hospital admission for antiarrhythmic drug initiation in atrial fibrillation","volume":"43","author":"Kim MH","year":"2009","unstructured":"Kim MH, Klingman D, Lin J, Pathak P, Battleman DS. Cost of hospital admission for antiarrhythmic drug initiation in atrial fibrillation. Ann. Pharmacother. 43(5), 840\u2013848 (2009).","journal-title":"Ann. Pharmacother."},{"key":"e_1_3_6_43_2","unstructured":"Dronedarone label (fda.gov). MULTAQ \u00ae (dronedarone) tablets for oral use Prescribing Information. www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/022425s007lbl.pdf (2021)."},{"key":"e_1_3_6_44_2","unstructured":"Amiodarone label (fda.gov). www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/018972s054lbl.pdf (2021)."},{"key":"e_1_3_6_45_2","unstructured":"Sotalol label (fda.gov). Sotalol IV (sotalol hydrochloride injection 10mL vial [15mg\/mL]). www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/022306s005lblrpl.pdf (2021)."},{"key":"e_1_3_6_46_2","unstructured":"Flecainide: Package Insert (Drugs.com). Flecainide: Package Insert \/ Prescribing Information. www.drugs.com\/pro\/flecainide.html (2021)."},{"key":"e_1_3_6_47_2","unstructured":"Propafenone label (fda.gov). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/019151s015lbl.pdf (2021)."},{"key":"e_1_3_6_48_2","unstructured":"MULTAQ Savings Card Program. MULTAQ \u00ae (dronedarone) Tablet 400 mg. www.multaq.com\/savings-and-support\/multaq-savings-card-program. (2023)."},{"issue":"12","key":"e_1_3_6_49_2","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1016\/j.amjcard.2019.09.008","article-title":"Meta-analysis comparing the relative risk of adverse events for amiodarone versus placebo","volume":"124","author":"Ruzieh M","year":"2019","unstructured":"Ruzieh M, Moroi MK, Aboujamous NM Meta-analysis comparing the relative risk of adverse events for amiodarone versus placebo. Am. J. Cardiol. 124(12), 1889\u20131893 (2019).","journal-title":"Am. J. Cardiol."},{"issue":"8","key":"e_1_3_6_50_2","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1056\/NEJM198702193160807","article-title":"Amiodarone","volume":"316","author":"Mason JW","year":"1987","unstructured":"Mason JW. Amiodarone. N. Engl. J. Med. 316(8), 455\u2013466 (1987).","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"e_1_3_6_51_2","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/europace\/eux274","article-title":"2017 HRS\/EHRA\/ECAS\/APHRS\/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation","volume":"20","author":"Calkins H","year":"2017","unstructured":"Calkins H, Hindricks G, Cappato R 2017 HRS\/EHRA\/ECAS\/APHRS\/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation. Europace 20(1), e1\u2013e160 (2017).","journal-title":"Europace"},{"key":"e_1_3_6_52_2","first-page":"271","article-title":"Outcomes following catheter ablation of atrial fibrillation in the UK: a single-centre cohort analysis","volume":"17","author":"Gunawardena RF","year":"2010","unstructured":"Gunawardena RF, Furniss SS, Shepherd E, Santarpia G, Lord SW, Bourke JP. Outcomes following catheter ablation of atrial fibrillation in the UK: a single-centre cohort analysis. Brit. J. Cardiol. 17, 271\u2013276 (2010).","journal-title":"Brit. J. Cardiol."},{"issue":"3","key":"e_1_3_6_53_2","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/clc.23309","article-title":"Efficacy and safety of dronedarone in patients with a prior ablation for atrial fibrillation\/flutter: insights from the ATHENA study","volume":"43","author":"Vamos M","year":"2020","unstructured":"Vamos M, Calkins H, Kowey PR Efficacy and safety of dronedarone in patients with a prior ablation for atrial fibrillation\/flutter: insights from the ATHENA study. Clin. Cardiol. 43(3), 291\u2013297 (2020).","journal-title":"Clin. Cardiol."},{"key":"e_1_3_6_54_2","doi-asserted-by":"publisher","DOI":"10.57264\/cer-2022-0196"},{"issue":"9","key":"e_1_3_6_55_2","doi-asserted-by":"crossref","first-page":"e007414","DOI":"10.1161\/CIRCEP.119.007414","article-title":"Catheter ablation versus medical therapy for atrial fibrillation: a systematic review and meta-analysis of randomized controlled trials","volume":"12","author":"Asad ZUA","year":"2019","unstructured":"Asad ZUA, Yousif A, Khan MS, Al-Khatib SM, Stavrakis S. Catheter ablation versus medical therapy for atrial fibrillation: a systematic review and meta-analysis of randomized controlled trials. Circ. Arrhythm Electrophysiol. 12(9), e007414 (2019).","journal-title":"Circ. Arrhythm Electrophysiol."},{"issue":"11","key":"e_1_3_6_56_2","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1001\/jama.2019.0335","article-title":"Effect of catheter ablation vs antiarrhythmic medication on quality of life in patients with atrial fibrillation: the CAPTAF randomized clinical trial","volume":"321","author":"Blomstrom-Lundqvist C","year":"2019","unstructured":"Blomstrom-Lundqvist C, Gizurarson S, Schwieler J Effect of catheter ablation vs antiarrhythmic medication on quality of life in patients with atrial fibrillation: the CAPTAF randomized clinical trial. JAMA 321(11), 1059\u20131068 (2019).","journal-title":"JAMA"},{"issue":"13","key":"e_1_3_6_57_2","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1001\/jama.2019.0693","article-title":"Effect of catheter ablation vs antiarrhythmic drug therapy on mortality, stroke, bleeding, and cardiac arrest among patients with atrial fibrillation: the CABANA randomized clinical trial","volume":"321","author":"Packer DL","year":"2019","unstructured":"Packer DL, Mark DB, Robb RA Effect of catheter ablation vs antiarrhythmic drug therapy on mortality, stroke, bleeding, and cardiac arrest among patients with atrial fibrillation: the CABANA randomized clinical trial. JAMA 321(13), 1261\u20131274 (2019).","journal-title":"JAMA"},{"issue":"13","key":"e_1_3_6_58_2","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1001\/jama.2019.0692","article-title":"Effect of catheter ablation vs medical therapy on quality of life among patients with atrial fibrillation: the CABANA randomized clinical trial","volume":"321","author":"Mark DB","year":"2019","unstructured":"Mark DB, Anstrom KJ, Sheng S Effect of catheter ablation vs medical therapy on quality of life among patients with atrial fibrillation: the CABANA randomized clinical trial. JAMA 321(13), 1275\u20131285 (2019).","journal-title":"JAMA"},{"key":"e_1_3_6_59_2","unstructured":"The SF-36v2 \u00ae Health Survey. Measure functional health and well-being from the patient's point of view with the SF-36v2 \u00ae Health Survey. www.qualitymetric.com\/health-surveys\/the-sf-36v2-health-survey\/. (2023)."},{"key":"e_1_3_6_60_2","unstructured":"EQ-5D. EUROQOL INSTRUMENTS. https:\/\/euroqol.org\/ (2023)."},{"issue":"1","key":"e_1_3_6_61_2","first-page":"30","article-title":"Impact of a pharmacy-cardiology collaborative management program during initiation of antiarrhythmic drugs","volume":"3","author":"Kibert JL","year":"2020","unstructured":"Kibert JL, Franck JB, Maltese Dietrich N, Quffa LH, Franck AJ. Impact of a pharmacy-cardiology collaborative management program during initiation of antiarrhythmic drugs. Clin. Pharm. Res. Rep. 3(1), 30\u201335 (2020).","journal-title":"Clin. Pharm. Res. Rep."}],"container-title":["Journal of Comparative Effectiveness Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/becarispublishing.com\/doi\/pdf\/10.57264\/cer-2023-0065","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,16]],"date-time":"2023-08-16T08:52:01Z","timestamp":1692175921000},"score":1,"resource":{"primary":{"URL":"https:\/\/becarispublishing.com\/doi\/10.57264\/cer-2023-0065"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":59,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["10.57264\/cer-2023-0065"],"URL":"https:\/\/doi.org\/10.57264\/cer-2023-0065","relation":{},"ISSN":["2042-6305","2042-6313"],"issn-type":[{"type":"print","value":"2042-6305"},{"type":"electronic","value":"2042-6313"}],"subject":[],"published":{"date-parts":[[2023,8]]},"article-number":"e230065"}}